Evidence map›Paper›PMID 33659024›Full record

ArticleFrontiers in genetics2021

Baozhong Yu, Xiang Zheng, Zejia Sun, Peng Cao, Jiandong Zhang, Wei Wang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Cells · 2023
    Article
  5. DNA and RNA Binding Proteins: From Motifs to Roles in Cancer.International journal of molecular sciences · 2022
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Baozhong YuDepartment of Urology, Affiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing, China.
Xiang ZhengDepartment of Clinical Medicine, Capital Medical University, Beijing, China.
Zejia SunDepartment of Urology, Affiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing, China.
Peng CaoDepartment of Clinical Medicine, Capital Medical University, Beijing, China.
Jiandong ZhangDepartment of Clinical Medicine, Capital Medical University, Beijing, China.
Wei WangDepartment of Urology, Affiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing, China.
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidences of renal cell carcinoma (RCC) increase in number each year and account for about 2-3% of all malignant tumors. Many patients have metastasis by the time of diagnosis, and their prognosis is poor. Therefore, it is essential that new diagnostic and prognostic markers for kidney cancer are identified. In this study, we assessed the potential of

Indexed as

biomarkersclear cell renal cell carcinomadiagnosisIFI16prognosis

Identifiers

PMID33659024
PMCPMC7917296
OpenAlexW3170060297

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.